The diagnostic journey patients with narcolepsy face is complex and multifaceted. Plagued by the Hollywood stigma and trope of comedic relief, narcolepsy is often misunderstood by patients and health care professionals (HCPs) alike. Misdiagnosis and diagnostic delay result in an oftentimes tumultuous journey for patients with this rare condition, further impacting their lower quality of life (QoL) due to untreated symptoms. It is imperative that HCPs recognize the signs, symptoms, and related QoL impact of narcolepsy in order to aid the patient in their diagnostic journey and, if possible, discuss referral to a sleep specialist.
The first episode of this CMEO BriefCase series on narcolepsy focuses on screening for narcolepsy based on patient presentation, description of function, and changes in QoL to facilitate initiation of a treatment plan to optimize patient outcomes.
Screen for narcolepsy based on patient presentation or patient or family/caregiver description of function and changes in QoL.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care practitioners, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Bogan reports the following financial relationships:
Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.
Dr. Doghramji reports the following financial relationships:
Advisory Board: Bayer; Eisai Inc.; and Idorsia Pharmaceuticals Ltd
Speakers Bureau: AbbVie Inc.; Eisai Inc.; Idorsia Pharmaceuticals Ltd; and Merck & Co., Inc.
Stock Shareholder (directly purchased): CVS Health Corporation and Pfizer Inc.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report::
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).